Odunayo O. Mugisho Buchanan Ocular Therapeutics Unit, Department of Ophthalmology and the New Zealand National Eye Centre University of Auckland Biography Publications Institution JoVE Articles Odunayo O. Mugisho has not added a biography. If you are Odunayo O. Mugisho and would like to personalize this page please email our Author Liaison for assistance. Publications Effect of Therapeutic UVC on Corneal DNA: Safety Assessment for Potential Keratitis Treatment The Ocular Surface. Apr, 2021 | Pubmed ID: 33610742 Connexin43 Hemichannel Block Inhibits NLRP3 Inflammasome Activation in a Human Retinal Explant Model of Diabetic Retinopathy Experimental Eye Research. 01, 2021 | Pubmed ID: 33285185 The Influence of Hyperglycemia on the Safety of Ultrasound in Retinal Pigment Epithelial Cells Cell Biology International. Mar, 2021 | Pubmed ID: 33049086 Connexin Therapeutics: Blocking Connexin Hemichannel Pores is Distinct from Blocking Pannexin Channels or Gap Junctions Neural Regeneration Research. Mar, 2021 | Pubmed ID: 32985469 Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy International Journal of Molecular Sciences. Dec, 2020 | Pubmed ID: 33396676 Characterization of Zinc Oxide Nanoparticle Cross-Linked Collagen Hydrogels Gels (Basel, Switzerland). Oct, 2020 | Pubmed ID: 33105715 Connexin43 Hemichannel Block Protects Against Retinal Pigment Epithelial Cell Barrier Breakdown Acta Diabetologica. Jan, 2020 | Pubmed ID: 31030263 Targeting Connexin Hemichannels to Control the Inflammasome: the Correlation Between Connexin43 and NLRP3 Expression in Chronic Eye Disease Expert Opinion on Therapeutic Targets. 10, 2019 | Pubmed ID: 31554417 Bradykinin Receptor-1 Activation Induces Inflammation and Increases the Permeability of Human Brain Microvascular Endothelial Cells Cell Biology International. Sep, 2019 | Pubmed ID: 31498530 Depot Formulations to Sustain Periocular Drug Delivery to the Posterior Eye Segment Drug Discovery Today. 08, 2019 | Pubmed ID: 30930148 Connexin43 Hemichannels: A Potential Drug Target for the Treatment of Diabetic Retinopathy Drug Discovery Today. 08, 2019 | Pubmed ID: 30690195 Connexin43 Hemichannel Block Protects Against the Development of Diabetic Retinopathy Signs in a Mouse Model of the Disease Journal of Molecular Medicine (Berlin, Germany). 02, 2019 | Pubmed ID: 30535867 Intravitreal Pro-inflammatory Cytokines in Non-obese Diabetic Mice: Modelling Signs of Diabetic Retinopathy PloS One. 2018 | Pubmed ID: 30133488 The Inflammasome Pathway is Amplified and Perpetuated in an Autocrine Manner Through Connexin43 Hemichannel Mediated ATP Release Biochimica Et Biophysica Acta. General Subjects. Mar, 2018 | Pubmed ID: 29158134 Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas International Journal of Molecular Sciences. Nov, 2017 | Pubmed ID: 29186067 소설 인간 오르가노피 망막 문화 기술의 특성화 Charisse Y. J. Kuo*1, Henry H. Louie1, Ilva D. Rupenthal1, Odunayo O. Mugisho*1 1Buchanan Ocular Therapeutics Unit, Department of Ophthalmology and the New Zealand National Eye Centre, University of Auckland JoVE 62046 Medicine
소설 인간 오르가노피 망막 문화 기술의 특성화 Charisse Y. J. Kuo*1, Henry H. Louie1, Ilva D. Rupenthal1, Odunayo O. Mugisho*1 1Buchanan Ocular Therapeutics Unit, Department of Ophthalmology and the New Zealand National Eye Centre, University of Auckland JoVE 62046 Medicine